NCT06568692 - A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

October 31, 2026

Conditions

Breast CancerTNBC - Triple-Negative Breast CancerHER2-negative Breast Cancer

Interventions

DRUG

PCS6422 and capecitabine

PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.

DRUG

Capecitabine

Commercially available capecitabine is a commonly used oral fluoropyrimidine.

Trial Locations (13)

11590

RECRUITING

Clinical Research Alliance, Westbury

21201

RECRUITING

University of Maryland Medical Center (UMMC), Baltimore

33165

RECRUITING

AP Medical Research, Miami

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

SCRI Oncology Partners, Nashville

44718

RECRUITING

Gabrail Cancer Center Research, Canton

46311

RECRUITING

Northwest Cancer Center, Dyer

78240

RECRUITING

Texas Oncology PA (San Antonio), San Antonio

78731

RECRUITING

Texas Oncology PA (Austin), Austin

85711

RECRUITING

Arizona Oncology Associates, Tucson

90067

RECRUITING

Valkyrie Clinical Trials, Los Angeles

93030

RECRUITING

FOMAT Medical Research, Oxnard

08901

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick